Antioxidant therapy in human endocrine disorders

Medical Science Monitor

Volumn 16, Issue 1, 2010, Pages

  Golbidi, Saeid ^a   Laher, Ismail ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antioxidant; Diabetes; Endocrine disease; Female infertility; Male infertility; Oxidative stress; Thyroid disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE; HEMOGLOBIN A1C; IRON; LYCOPENE; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; SELENIUM; SELENOMETHIONINE; SODIUM SELENITE; THIOCTIC ACID; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROXINE; UBIDECARENONE; VITAMIN B GROUP; ZINC;

APOPTOSIS; AUTOIMMUNE THYROIDITIS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG MEGADOSE; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; FEMALE INFERTILITY; GERM CELL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; MALE INFERTILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; THYROID DISEASE; TREATMENT DURATION; VASCULAR DISEASE;

ANTIOXIDANTS; ASCORBIC ACID; DIABETES MELLITUS; FEMALE; HUMANS; INFERTILITY; MALE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; THIOCTIC ACID; THYROID DISEASES; UBIQUINONE; VITAMIN E;

EID: 75149139411     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (254)

1. Rahman K: Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging, 2007; 2: 219-36
2. Valko M, Rhodes CJ, Moncol J et al: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact, 2006; 160: 1-40
3. Kovacic P, Jacintho JD: Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem, 2001; 8: 773-96
4. Ridnour LA, Isenberg JS, Espey MG et al: Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci USA, 2005; 102: 13147-52
5. Valko M, Morris H, Mazúr M et al: Oxygen free radical generating mechanisms in the colon: do the semiquinones of vitamin K play a role in the aetiology of colon cancer? Biochim Biophys Acta, 2001; 1527: 161-66
6. Malhotra JD, Kaufman RJ: Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal, 2007; 9: 2277-93
7. Halliwell B: Biochemistry of oxidative stress. Biochem Soc Trans, 2007; 35: 1147-50
8. Valko M, Leibfritz D, Moncol J et al: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol, 2007; 39: 44-84
9. Duckworth WC: Hyperglycemia and cardiovascular disease. Curr Atheroscler, 2001; 3: 383-91
10. Bashan N, Kovsan J, Kachko I et al: Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev, 2009; 89: 27-71
11. Vega-Lopez S, Devaraj S, Jialal I: Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med, 2004; 52: 24-32
12. Oberg BP, McMenamin E, Lucas FL et al: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int, 2004; 65: 1009-16
13. Ceriello A, Mercuri F, Quagliaro L et al: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia, 2001; 44: 834-38
14. Turko IV, Marcondes S, Murad F: Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA: 3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol, 2001; 281: H2289-94
15. Guzik TJ, West NE, Black E et al: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res, 2000; 86: E85-90
16. Guzik TJ, Mussa S, Gastaldi D et al: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation, 2002; 105: 1656-62
17. Aliciguzel Y, Ozen I, Aslan M, Karayalcin U: Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med, 2003; 142: 172-77
18. Maritim AC, Sanders RA, Watkins JB III: Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol, 2003; 17: 24-38
19. Kitada M, Koya D, Sugimoto T et al: Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes, 2003; 52: 2603-14
20. Etoh T, Inoguchi T, Kakimoto M et al: Increased expression of NAD(P) H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia, 2003; 46: 1428-37
21. Green K, Brand MD, Murphy MP: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes, 2004; 53: S110-18
22. Nishikawa T, Edelstein D, Du XL et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature, 2000; 404: 787-90
23. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature, 2001; 414: 813-20
24. Boullier A, Bird DA, Chang MK et al: Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci, 2001; 947: 214-22
25. Taniyama Y, Griendling KK: Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension, 2003; 42: 1075-81
26. Liu Y, Gutterman DD: The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascul Pharmacol, 2002; 38: 43-49
27. Liu Y, Terata K, Chai Q et al: Peroxynitrite inhibits Ca2+-activated K+ channel activity in smooth muscle of human coronary arterioles. Circ Res 2002; 91: 1070-76
28. Soriano FG, Virag L, Szabo C: Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med, 2001; 79: 437-48
29. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation, 2003; 108: 1912-16
30. Huang HY, Caballero B, Chang S et al: Multivitamin/mineral supplements and prevention of chronic disease. Evid Rep Technol Assess (Full Rep), 2006; 139: 1-117
31. McCarty MF: Complementary measures for promoting insulin sensitivity in skeletal muscle. Med Hypotheses, 1998; 51: 451-94
32. Paolisso G, D'Amore A, Galzerano D et al: Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care, 1993; 16: 1433-37
33. Manzella D, Barbieri M, Ragno E, Paolisso G: Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr, 2001; 73: 1052-57
34. Park S, Choi SB: Effects of alpha-tocopherol supplementation and continuous subcutaneous insulin infusion on oxidative stress in Korean patients with type 2 diabetes. Am J Clin Nutr, 2002; 75: 728-33
35. Gaede P, Poulsen HE, Parving HH, Pedersen O: Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med, 2001; 18: 756-60
36. Ruhe RC, McDonald RB: Use of antioxidant nutrients in the prevention and treatment of type 2 diabetes. J Am Coll Nutr, 2001; 5: 363s-69s
37. Traber MG: Does vitamin E decrease heart attack risk? Summary and implications with respect to dietary recommendations. J Nutr, 2001; 131: 395s-97s
38. Bonfigli AR, Pieri C, Manfrini S et al: Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients. Diabetes Nutr Metab, 2001; 14: 71-77
39. Devaraj S, Chan AV Jr, Jialal I: Alpha-Tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. Diabetes Care, 2002; 25: 524-29
40. Lonn EM, Yusuf S: Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. Can J Cardiol, 1997; 13: 957-65
41. Jialal I, Fuller CJ: Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Can J Cardiol, 1995; 11: 97G-103G
42. Stampfer MJ, Hennekens CH, Manson JE et al: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med, 1993; 328: 1444-49
43. Knekt P, Reunanen A, Järvinen R et al: Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol, 1994; 139: 1180-89
44. Yusuf S, Dagenais G, Pogue J et al: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342: 154-60
45. de Gaetano G; Collaborative Group of the Primary Prevention Project: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet, 2001; 357: 89-95
46. Lonn E: Modifying the natural history of atherosclerosis: the SECURE trial. Int J Clin Pract Suppl, 2001; 117: 13-18
47. Greenberg S, Frishman WH: Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol, 1990; 30: 596-608
48. Tran MT, Mitchell TM, Kennedy DT, Giles JT: Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy, 2001; 21: 797-806
49. Specialty supplements are the bright spot in U.S. dietary supplement market - focus 2003: food additives/nutraceuticals/vitamins - industry overview. Chemical Market Reporter, July 2003. Accessed online March 1, 2005 at: http://www.dietarticles.com/diet/darticles/low-fatdiet/low-fat-dietarticle- 11080.html
50. Crane FL, Navas P: The diversity of coenzyme Q function. Mol Aspects Med, 1997; 18: 51-56
51. McCarty MF: Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation? Med Hypoth, 1999; 53: 300-4
52. Bonakdar RA, Guarneri E: Coenzyme Q10. Am Fam Physician, 2005; 72: 1065-70
53. Chew GT, Watts GF: Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. QJM, 2004; 97: 537-48
54. Overvad K, Diamant B, Holm L et al: Coenzyme Q10 in health and disease. Eur J Clin Nutr, 1999; 53: 764-70
55. Langsjoen PH, Langsjoen AM: Overview of the use of CoQ10 in cardiovascular disease. Biofactors, 1999; 9: 273-84
56. Hargreaves IP, Duncan AJ, Heales SJ, Land JM: The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. Drug Saf, 2005; 28: 659-76
57. Greenberg S, Frishman WH: Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol, 1990; 30: 596-608
58. Henriksen JE, Andersen CB, Hother-Nielsen O et al: Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med, 1999; 16: 312-18
59. Eriksson JG, Forsén TJ, Mortensen SA, Rohde M: The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors, 1999; 9: 315-18
60. Carr AC, Frei B: Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr, 1999; 69: 1086-107
61. Maxwell S, Thomason H, Sandler D et al: Antioxidant status in patients with uncomplicated insulin-dependent and noninsulin dependent diabetes mellitus. Euro J Clin Invest, 1997; 27: 484-90
62. Sundaram R, Bhaskar A, Vijayalingam S et al: Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Science, 1996; 90: 255-60
63. Ceriello A, Bortolotti N, Crescentini A et al: Antioxidant defenses are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Euro J Clin Invest, 1998; 28: 329-33
64. Paolisso G, Balbi V, Volpe C et al: Metabolic benefits deriving from chronic vitamin C supplementation in aged noninsulin-dependent diabetes. J Am Coll Nutr, 1995; 14: 387-92
65. Paolisso G, D'Amore A, Balbi V et al: Plasma vitamin C affects glucose homeostasis in healthy subjects and in noninsulin-dependent diabetes. Am J Physiol, 1994; 266: E261-68
66. Osqanian SK, Stampfer MJ, Rimm E et al: Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol, 2003; 42: 246-52
67. Kushi LH, Folsom AR, Prineas RJ et al: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med, 1996; 334: 1156-62
68. Losonczy KG, Harris TB, Havlik RJ: Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr, 1996; 64: 190-96
69. Reed LJ: From lipoic acid to multi-enzyme complexes. Protein Sci, 1998; 7: 220-24
70. Busby RW, Schelvis JPM, Yu DS et al: Lipoic acid biosynthesis: LipA is an iron-sulphur protein. J Am Chem Soc, 1999; 121: 4706-7
71. Schmidt AM, Hori O, Brett J et al: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb, 1994; 14: 1521-28
72. Wada H, Shintani D, Ohlrogge J: Why do mitochondria synthesize fatty acids? Evidence for involvement in lipoic acid production. Proc Natl Acad Sci USA, 1997; 94: 1591-96
73. Biewenga GP, Haenen GR, Bast A: The pharmacology of the antioxidant lipoic acid. Gen Pharmacol, 1997; 29: 315-31
74. Jones W, Li X, Qu ZC et al: Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radic Biol Med, 2002; 33: 83-93
75. Singh U, Jialal I: Alpha-lipoic acid supplementation and diabetes. Nutr Rev, 2008; 66: 646-57
76. Packer L: alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. Drug Metab Rev, 1998; 30: 245-75
77. Zhang WJ, Frei B: Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J, 2001; 15: 2423-32
78. Mizuno M, Packer L: Effects of alpha-lipoic acid and dihydrolipoic acid on expression of proto-oncogene c-fos. Biochem Biophys Res Commun, 1994; 200: 1136-42
79. Jacob S, Henriksen EJ, Schiemann AL et al: Enhancement of glucose disposal in patients with type 2 diabetes by alphalipoic acid. Arzneimittelforschung, 1995; 45: 872-74
80. Jacob S, Henriksen EJ, Tritschler HJ et al: Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes, 1996; 104: 284-88
81. Jacob S, Rett K, Henriksen EJ et al: Thioctic acid - effects on insulin sensitivity and glucose-metabolism. Biofactors, 1999; 10: 169-74
82. Evans JL, Heymann CJ, Goldfine ID et al: Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr Pract, 2002; 8: 29-35
83. Konrad T, Vicini P, Kusterer K et al: alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care, 1999; 22: 280-87
84. Kamenova P: Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens), 2006; 5: 251-58
85. Androne L, Gavan NA, Veresiu IA, Orasan R: In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000; 14: 327-30
86. Ziegler D, Reljanovic M, Mehnert H, Gries FA: Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes, 1999; 107: 421-30
87. Ziegler D, Hanefeld M, Ruhnau KJ et al: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 1995; 38: 1425-33
88. Ziegler D, Hanefeld M, Ruhnau KJ et al: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care, 1999; 22: 1296-301
89. Reljanovic M, Reichel G, Rett K et al: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res, 1999; 31: 171-79
90. Ou P, Tritschler HJ, Wolff SP: Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem Pharmacol, 1995; 50: 123-26
91. Haak E, Usadel KH, Kusterer K et al: Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes, 2000; 108: 168-74
92. Strokov IA, Manukhina EB, Bakhtina LY et al: The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. Bull Exp Biol Med, 2000; 130: 986-90
93. Hofmann MA, Schiekofer S, Kanitz M et al: Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care, 1998; 21: 1310-16
94. Kähler W, Kuklinski B, Rühlmann C, Plötz C: Diabetes mellitus - a free radical-associated disease. Results of adjuvant antioxidant supplementation. Z Gesamte Inn Med, 1993; 48: 223-32
95. Heitzer T, Finckh B, Albers S et al: Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med, 2001; 31: 53-61
96. Morcos M, Borcea V, Isermann B et al: Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract, 2001; 52: 175-83
97. Krajcovicová-Kudlácková M, Simoncic R, Béderová A et al: Correlation of carnitine levels to methionine and lysine intake. Physiol Res, 2000; 49: 399-402
98. Ferrannini E, Buzzigoli G, Bevilacqua S et al: Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol, 1988; 255: E946-52
99. Capaldo B, Napoli R, Di Bonito P et al: Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract, 1991; 14: 191-95
100. Mingrone G, Greco AV, Capristo E et al: L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr, 1999; 18: 77-82
101. Brevetti G, Diehm C, Lambert D: European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol, 1999; 34: 1618-24
102. Ragozzino G, Mattera E, Madrid E et al: Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. Drugs RD, 2004; 5: 185-90
103. De Grandis D, Minardi C: Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs RD, 2002; 3: 223-31
104. Victor VM, Rocha M: Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr Pharm Des, 2006; 13: 845-63
105. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes, 1998; 47: 859-66
106. Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med, 2001; 18: 945-59
107. Ishii H, Jirousek MR, Koya D et al: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science, 1996; 272: 728-31
108. The PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes, 2005; 54: 2188-97
109. Tesfaye S, Tandan R, Bastyr EJ III et al: Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care, 2007; 30: 2626-32
110. Vinik AI, Bril V, Kempler P et al: Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor Ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, doubleblind clinical trial. Clin Ther, 2005; 27: 1164-80
111. Idris I, Donnelly R: Protein kinase C beta inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diab Vasc Dis Res, 2006; 3: 172-78
112. Mehta NN, Sheetz M, Price K et al: Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther, 2009; 23: 17-24
113. No authors listed. Ruboxistaurin: LY 333531. Drugs RD, 2007; 8(3): 193-99
114. Garcia Soriano F, Pacher P, Mabley JG et al: Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly-(ADP-ribose) polymerase activation. Circ Res, 2001; 89: 684-91
115. Pacher P, Liaudet L, Garcia Soriano F et al: The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes, 2002; 51: 514-21
116. Szabo C, Mabley JG, Moeller SM et al: Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med, 2002; 8: 571-80
117. Garcia Soriano F, Virag L, Jagtap P et al: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med, 2001; 7: 108-13
118. Zingarelli B, Salzman AL, Szabo C: Genetic disruption of poly (ADPribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res, 1998; 83: 85-94
119. Szabo C, Virag L, Cuzzocrea S et al: Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA, 1998; 95: 3867-72
120. Oliver FJ, Menissier-de Murcia J et al: Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J, 1999; 18: 4446-54
121. Virag L, Salzman AL, Szabo C: Poly(ADPribose) synthetase activation mediates mitochondrial injury during oxidantinduced cell death. J Immunol, 1998; 161: 3753-59
122. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature, 2001; 414: 813-20
123. Rolo AP, Palmeira CM: Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol, 2006: 212: 167-78
124. Gabriely I, Yang XM, Cases JA et al: Hyperglycemia modulates angio-tensinogen gene expression. Am J Physiol, 2001; 281: R795-802
125. Munzel T, Keaney JF: Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation, 2001; 104: 1571-74
126. Nickenig G, Harrison DG: The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation, 2002; 105: 393-96
127. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res, 1994; 74: 1141-48
128. Chaturvedi N, Sjolie AK, Stephenson JM et al: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet, 1998; 351: 28-31
129. No authors listed. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000; 355: 253-59
130. Lewis EJ, Hunsicker LG, Clarke WR et al: Collaborative Study Group, Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001; 345: 851-60
131. Brenner BM, Cooper ME, de Zeeuw D et al: RENAAL Study Investigators, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001; 345: 861-69
132. Takano H, Komuro I: Roles of peroxisome proliferators-activated receptor γ in cardiovascular disease. J Diabetes Complicat, 2002; 16: 198-214
133. Bishop-Bailey D: Peroxisome proliferators-activated receptors in the cardiovascular system. Br J Pharmacol, 2000; 129: 823-34
134. Ricote M, Li AC, Wilson TM et al: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 1998; 391: 79-82
135. Jiang C, Ting AT, Seed B: PPARg agonist inhibits production of monocyte inflammatory cytokines. Nature, 1998; 391: 82-86
136. Pasceri V, Wu HD, Willerson JT, Yeh ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferatoractivated receptor-γ activators. Circulation, 2000; 101: 235-38
137. Da Ros R, Assaloni R, Ceriello A: The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med, 2004; 21: 1249-52
138. Bagi Z, Koller A, Kaley G: Peroxisome proliferator-activated receptor-gamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles in type 2 diabetes. Am J Physiol, 2004; 286: H742-48
139. Wayman NS, Hattori Y, McDonald MC et al: Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J, 2002; 16: 1027-40
140. Tao L, Liu HR, Gao E et al: Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation, 2003; 108: 2805-11
141. Shimabukuro M, Higa S, Shinzato T et al: Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism, 1995; 45: 1168-73
142. Zhu P, Lu P, Xu P, Schartz GC: Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation, 2000; 101: 1165-71
143. Khandoudi N, Delerive P, Berrebi-Bertrand I et al: Rosiglitazone, a peroxisome proliferator-activated receptor-g, inhibits the jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/ reperfusion injury. Diabetes, 2002; 51: 1507-14
144. Yin T, Sandhu G, Wolfgang CD et al: Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem, 1997; 272: 19943-50
145. Uehata M, Ishizaki T, Satoh H et al: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature, 1997; 389: 990-94
146. Van Aelst L, D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev, 1997; 11: 2295-22
147. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitor. Circulation, 1998; 273: 24266-71
148. Lauf U, LiaoJK: Targeting Rho in cardiovascular disease. Circ Res, 2000; 87: 526-28
149. Laufs U, Liao JK: Direct vascular effects of HMG CoA reductases inhibitors. Trends Cardiovasc Med, 2000; 10: 143-48
150. Bates K, Ruggeroli CE, Goldman S, Gaballa MA: Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol, 2002; 283: H768-75
151. Wagner AH, Kohler T, Ruckschloss U et al: Improvement of nitric oxide-dependent vasodilation by HMGCoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 2000; 20: 61-69
152. Vecchione C, Brandes RP: Withdrawal of 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res, 2002; 91: 173-79
153. Ceriello A, Taboga C, Tonutti L et al: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Effects of short- and long-term simvastatin treatment. Circulation, 2002; 106: 1211-18
154. Ceriello A, Quagliaro L, Piconi L et al: Effect of postprandial hypertri-glyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes, 2004; 53: 701
155. Shishehbor MH, Aviles RJ, Brennan ML et al: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA, 2003; 289: 1675-80
156. Agarwal A, Gupta S, Sharma R: Oxidative stress and its implications in female infertility - a clinician's perspective. Reprod Biomed Online, 2005; 11: 641-50
157. Duckitt K: Infertility and subfertility. Clin Evid, 2003; 9: 2044-73
158. Saleh RA, Agarwal A, Sharma RK et al: Effect of cigarette smoking on levels of seminal oxidative stress in infertile men: a prospective study. Fertil Steril, 2002; 78: 491-99
159. Maneesh M, Dutta S, Chakrabarti A, Vasudevan DM: Alcohol abuse-duration dependent decrease in plasma testosterone and antioxidants in males. Indian J Physiol Pharmacol, 2006; 50: 291-96
160. Singer G, Granger DN: Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance. Microcirculation, 2007; 14: 375-87
161. Samanta L, Chainy GB: Comparison of hexachlorocyclohexaneinduced oxidative stress in the testis of immature and adult rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 1997; 118: 319-27
162. Aitken RJ, Koopman P, Lewis SEM: Seeds of concern. Nature, 2004; 432: 48-52
163. Koizumi T, Li ZG: Role of oxidative stress in single-dose, cadmium induced testicular cancer. J Toxicol Environ Health, 1992; 37: 25-36
164. Reddy MM, Mahipal SV, Subhashini J et al: Bacterial lipopolysaccharide- induced oxidative stress in the impairment of steroidogenesis and spermatogenesis in rats. Reprod Toxicol, 2006; 22: 493-500
165. Agbaje IM, Rogers DA, McVicar CM et al: Insulin dependant diabetes mellitus: implications for male reproductive function. Hum Reprod, 2007; 22: 1871-77
166. Oberg BP, McMenamin E, Lucas FL et al: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int, 2004; 65: 1009-16
167. Fretz PC, Sandlow JI: Varicocele: current concepts in pathophysiology, diagnosis, and treatment. Urol Clin North Am, 2002; 29: 921-38
168. Arnon J, Meirow D, Lewis-Roness H, Ornoy A: Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update, 2001; 7: 394-403
169. De Rosa M, Zarrilli S, Paesano L et al: Traffic pollutants affect fertility in men. Hum Reprod, 2003; 18: 1055-61
170. Tremellen K: Oxidative stress and male infertility, a clinical perspective. Hum Reprod Update, 2008; 3: 243-58
171. Turner TT, Lysiak JJ: Oxidative stress: a common factor in testicular dysfunction. J Androl, 2008; 5: 488-98
172. Patel SR, Sigman M: Antioxidant therapy in male infertility. Urol Clin North Am, 2008; 35: 319-30
173. Suleiman SA, Ali ME, Zaki ZM et al: Lipid peroxidation and human sperm motility: protective role of vitamin E. J Androl, 1996; 17: 530-37
174. Therond P, Auger J, Legrand A, Jouannet P: Alpha-tocopherol in human spermatozoa and seminal plasma: relationships with motility, antioxidant enzymes and leukocytes. Mol Hum Reprod, 1996; 2: 739-44
175. Ammar LK, Feki-Chakroun N, Rebai T et al: Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men. Arch Androl, 2003; 49: 83-94
176. Kessopoulou E, Powers HJ, Sharma KK et al: A double blind randomized placebo cross over controlled trial using the antioxidant vitamine E to treat reactive oxygen species associated male infertility. Fertil Steril, 1995; 64: 825-31
177. Rolf C, Cooper TG, Yeung CH, Nieschlag E: Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod, 1999; 14: 1028-33
178. Buettner GR: The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys, 1993; 300: 535-43
179. Lewis SE, Sterling ES, Young IS, Thompson W: Comparison of individual antixoidants of sperm and seminal plasma in fertile and infertile men. Fertil Steril, 1997; 67: 142-47
180. Mostafa T, Tawadrous G, Roaia MM et al: Effect of smoking on seminal plasma ascorbic acid in infertile and fertile males. Andrologia, 2006; 38: 221-24
181. Kodama H, Yamaguchi R, Fukuda J et al: Increased oxidative deoxyri-bonucleic acid damage in the spermatozoa of infertile male patients. Fertil Steril, 1997; 68: 519-24
182. Song GL, Norkus EP, Lewis V: Relationship between seminal ascorbic acid and sperm DNA integrity in infertile men. Int J Androl, 2006; 29: 569-75
183. Greco E, Iacobelli M, Rienzi L et al: Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. J Androl, 2005; 26: 349-53
184. Lenzi A, Gandini L, Picardo M: A rationale for glutathione therapy. Hum Reprod, 1998; 13: 1419-22
185. Raijmakers MT, Roelofs HM, Steegers EA et al: Glutathione and glutathione S-transferases A1-1 and P1-1 in seminal plasma may play a role in protecting against oxidative damage to spermatozoa. Fertil Steril, 2003; 79: 169-72
186. Kodama H, Yamaguch R, Fukuda J et al: Increased oxidative deoxyri-bonucleic acid damage in the spermatozoa of infertile male patients. Fertil Steril, 1997; 68: 519-24
187. Thomas SR, Neuzil J, Stocker R: Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler Thromb Vasc Biol, 1996; 16: 687-96
188. Alleva R, Scararmucci A, Mantero F et al: The protective role of ubiquinol-10 against formation of lipid hydroperoxides in human seminal fluid. Mol Aspects Med, 1997; 18: S221-28
189. Mancini A, Conte B, De Marinis L et al: Coenzyme Q10 levels in human seminal fluid: diagnostic and clinical implications. Mol Aspects Med, 1994; 15(Suppl.): s249-55
190. Lewin A, Lavon H: The effect of coenzyme Q10 on sperm motility and function. Mol Aspects Med, 1997; 18: s213-19
191. Balercia G, Mosca F, Mantero F et al: Coenzyme Q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril, 2004; 81: 93-98
192. Siddiq FM, Sigman M: A new look at the medical management of infertility. Urol Clin North Am, 2002; 29: 949-63
193. Matalliotakis I, koumantaki Y, Evageliou A et al: L-carnitine levels in the seminal plasma of fertile and infertile men: correlation with sperm quality. Int J Fertil Womens Med, 2000; 45: 236-40
194. Vicari E, Calogero AE: Effects of treatment with carnitines in infertile patients with prostate-vesiculo-epididymitis. Hum Reprod, 2001; 16: 2338-42
195. Gurbuz B, Yalti S, Ficicioglu C, Zehir K: Relationship between semen quality and seminal plasma total carnitine in infertile men. J Obstet Gynaecol, 2003; 23: 653-56
196. Soufir JC, Ducot B, Marson J et al: Levels of seminal free L(-) carnitine in fertile and infertile men. Int J Androl, 1984; 7: 188-97
197. Costa M, Canale D, Filicori M et al: L-carnitine in idiopathic astheno-zoospermia: a multicenter study. Italian Study Group on Carnitine and Male Infertility. Andrologia, 1994; 26: 155-59
198. Palan P, Naz R: Changes in various antioxidant levels in human seminal plasma related to immunoinfertility. Arch Androl, 1996; 36: 139-43
199. Goal A, Chopra M, Lwaleed BA et al: The effects of dietary lycopene supplementation on human seminal plasma. BJU Int, 2007; 99: 1456-60
200. Gupta NP, Kumar R: Lycopene therapy in idiopathic male infertility, a preliminary report. Int Urol Nephrol, 2002; 34: 369-72
201. Riley JC, Behrman HR: Oxygen radicals and reactive oxygen species in reproduction. Proc Soc Exp Biol Med, 1991; 198: 781-91
202. Sugino N, Karube-Harada A, Taketani T et al: Withdrawal of ovarian steroids stimulates prostaglandin F2alpha production through nuclear factor kappa B activation via oxygen radicals in human endometrial stromal cells: potential relevance to menstruation. J Reprod Dev, 2004; 50: 215-25
203. Shiotani M, Noda Y, Narimoto K et al: Immunohistochemical localization of superoxide dismutase in the human ovary. Hum Reprod, 1991; 6: 1349-53
204. Behrman HR, Kodaman PH, Preston SL, Gao S: Oxidative stress and the ovary. J Soc Gynecol Investig, 2001; 8: s40-42
205. Sugino N, Karube-Harada A, Taketani T et al: Withdrawal of ovarian steroids stimulates prostaglandin F2alpha production through nuclear factor-kappaB activation via oxygen radicals in human endometrial stromal cells: potential relevance to menstruation. J Reprod Dev, 2004; 50: 215-25
206. Riley JC, Behrman HR: Oxygen radicals and reactive oxygen species in reproduction. Proc Soc Exp Biol Med, 1991; 198: 781-91
207. Tamate K, Sengoku K, Ishikawa M: The role of superoxide dismutase in the human ovary and fallopian tube. J Obstet Gynaecol, 1995; 21: 401-9
208. de Bruin JP, Dorland M, Spek ER et al: Ultrastructure of the resting ovarian follicle pool in healthy young women. Biol Reprod, 2002; 66: 1151-60
209. Myatt L, Cui X: Oxidative stress in the placenta. Histochem Cell Biol, 2004; 122: 369-82
210. Fainaru O, Almog B, Pinchuk I et al: Active labour is associated with increased oxidisibility of serum lipids ex vivo. BJOG, 2002; 109: 938-41
211. Mocatta TJ, Winterbourn CC, Inder TE, Darlow BA: The effect of gestational age and labour on markers of lipid and protein oxidation in cord plasma. Free Radic Res, 2004; 38: 185-91
212. Wall PD, Pressman EK, Woods JR Jr: Preterm premature ruptures of the membranes and antioxidants: the free radical connection. J Perinat Med, 2002; 30: 447-57
213. Pressman EK, Cavanaugh JL, Mingione M et al: Effects of maternal antioxidant supplementation on maternal and fetal antioxidant levels: a randomized, double-blind study. Am J Obstet Gynecol, 2003; 189: 1720-25
214. Szczepańska M, Koźlik J, Skrzypczak J, Mikołajczyk M: Oxidative stress may be a piece in the endometriosis puzzle. Fertil Steril, 2003; 79: 1288-93
215. Van Langendonckt A, Casanas-Roux F, Donnez J: Oxidative stress and peritoneal endometriosis. 2002; 77: 861-70
216. Polak G, Kozioł-Montewka M, Gogacz M et al: Total antioxidant status of peritoneal fluid in infertile women. Eur J Obstet Gynecol Reprod Biol, 2001; 94: 261-63
217. Dong M, Shi Y, Cheng Q, Hao M. Increased nitric oxide in peritoneal fluid from women with idiopathic infertility and endometriosis. J Reprod Med, 2001; 46(10): 887-91
218. Agarwal A, Allamaneni SS: Role of free radicals in female reproductive diseases and assisted reproduction. Reproductive BioMedicine Online, 2004; 9: 338-47
219. Igarashi M: Augmentative effect of ascorbic acid upon induction of human ovulation in Clomiphene-ineffective anovulatory women. Int J Fertil, 1977; 22: 168-73
220. Henmi H, Endo T, Kitajima Y et al: Effects of ascorbic acid supplementation on serum progesterone levels in patients with a luteal phase defect. Fertil Steril, 2003; 80: 459-61
221. Crha I, Hrubá D, Ventruba P et al: Ascorbic acid and infertility treatment. Cent Eur J Public Health, 2003; 11: 63-67
222. Griesinger G, Franke K, Kinast C et al: Ascorbic acid supplement during luteal phase in IVF. J Assist Reprod Genet, 2002; 19: 164-68
223. Rumbold A, Crowther CA: Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev, 2005; 18: CD004072
224. Rumbold A, Middleton P, Crowther CA: Vitamin supplementation for preventing miscarriage. Cochrane Database Syst Rev, 2005; 18(2): CD004073
225. Westphal LM, Polan ML, Trant AS, Mooney SB: A nutritional supplement for improving fertility in women: a pilot study. J Reprod Med, 2004; 49: 289-93
226. Sundaram V, Hanna AN, Koneru L et al: Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab, 1997; 83: 3421-24
227. Brix TH, Kyvik KO, Hegedüs L: What is the evidence of genetic factors in the etiology of Graves' disease? A brief review. Thyroid, 1998; 8: 727-34
228. Lorini R, Gastaldi R, Traggiai C, Perucchin PP: Hashimoto's Thyroiditis. Pediatr Endocrinol Rev, 2003; 1: 205-11
229. Pereira B, Rosa LF, Safi DA et al: Control of superoxide dismutase, catalase and glutathione peroxidase activities in rat lymphoid organs by thyroid hormones. J Endocrinol, 1994; 140: 73-77
230. Resch U, Helsel G, Tatzber F, Sinzinger H: Antioxidant status in thyroid dysfunction. Clin Chem Lab Med, 2002; 40: 1132-24
231. Guerrero A, Pamplona R, Portero-Otin M et al: Effect of thyroid status on lipid composition and peroxidation in the mouse liver. Free Radic Biol Med, 1999; 26: 73-80
232. Nishiki K, Erecinska M, Wilson DF, Cooper S: Evaluation of oxidative phosphorylation in hearts from euthyroid, hypothyroid, and hyperthyroid rats. Am J Physiol, 1978; 235: C212-19
233. Swaroop A, Ramasarma T: Heat exposure and hypothyroid conditions decrease hydrogen peroxide generation in liver mitocondria. Biochem J, 1985; 226: 403-8
234. Baskol G, Atmaca H, Tanriverdi F et al: Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment. Exp Clin Endocrinol Diabetes, 2007; 115: 522-26
235. Erdamar H, Demirci H, Yaman H et al: The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Clin Chem Lab Med, 2008; 46: 1004-10
236. Duntas LH: Oxidants, antioxidants in physical exercise and relation to thyroid function. Horm Metab Res, 2005; 37: 572-76
237. Morini P, Casalino E, Sblanco C, Landriscina C: The response of rat liver lipid peroxidation, antioxidant enzyme activities and glutathione concentration of the thyroid hormone. Int J Biochem, 1991; 23: 1025-30
238. Asayama K, Dobashi K, Hayashibe H et al: Lipid peroxidation and free radical scavengers in thyroid dysfunction in the rat: a possible mechanism of injury to heart and skeletal muscle in hyperthyroidism. Endocrinology, 1987; 121: 2112-18
239. Bianchi G, Solaroli E, Zaccheroni V et al: Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: effect of treatment. Horm Metab Res, 1999; 31: 620-24
240. Andryskowski G, Owczarek T: The evaluation of selected oxidative stress parameters in patients with hyperthyroidism. Pol Arch Med Wewn, 2007; 117: 285-89
241. Abalovich M, Llesuy S, Gutierrez S, Repetto M: Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf), 2003; 59(3): 321-27
242. Bacic-Vrca V, Skreb F, Cepelak I et al: The effect of antioxidant supplementation on superoxide dismutase activity, Cu and Zn levels, and total antioxidant status in erythrocytes of patients with Graves' disease. Clin Chem Lab Med, 2005; 43(4): 383-88
243. Adali M, Inal-Erden M, Akalin A, Efe B: Effects of propylthiouracil, propranolol, and vitamin E on lipid peroxidation and antioxidant status in hyperthyroid patients. Clin Biochem, 1999; 32: 363-67
244. Rotruck JT, Pope AL, Ganther HE et al: Selenium: biochemical role as component of glutathione peroxidase. Science, 1973; 179: 588-90
245. Bianco AC, Salvatore D, Gereben B et al: Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews, 2002; 23: 38-89
246. Brown KM, Arthur JR: Selenium, selenoproteins and human health: a review. Public Health and Nutrition, 2001; 4: 593-99
247. 2-generating system modulates protein iodination and the activity of the pentose phosphate pathway in dog thyroid. Endocrinology, 1991; 128: 779-85
248. 2 and iodide during in vitro thyroglobulin iodination. Mol Cell Endocrinol, 1986; 46: 149-54
249. Contempre B, Denef JF, Dumont JE, Many MC: Selenium deficiency aggravates the necrotizing effects of a high iodide dose in iodine deficient rats. Endocrinology, 1993; 132: 1866-68
250. Contempre B, Le-Moine O, Dumont JE et al: Selenium deficiency and thyroid fibrosis. A key role for macrophages and transforming growth factor β (TGF-β). Mol Cell Endocrinol, 1996; 124: 7-15
251. Gärtner R, Gasnier BC, Dietrich JW et al: Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab, 2002; 87: 1687-91
252. Derumeaux H, Valeix P, Castetbon K et al: Association of selenium with thyroid volume and echostructure in 35- to 60-year-old French adults. Eur J Endocrinol, 2003; 148: 309-15
253. Duntas LH, Mantzou E, Koutras DA: Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol, 2003; 148: 389-93
254. Karanikas G, Schuetz M, Kontur S et al: No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid, 2008; 18: 7-12